Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplementary Figure S1 a

Published byありかつ きせんばる Modified over 7 years ago

Similar presentations

Presentation on theme: "Supplementary Figure S1 a"— Presentation transcript:

1 Supplementary Figure S1 a
VEGF 【H460】 【HCC2429】 0Gy 42kDa 42kDa 8Gy 42kDa 42kDa β-actin 45kDa 45kDa s 　 (h) s 　 (h) b Hes1 【H460】 【HCC2429】 0Gy 8Gy β-actin s 　 (h) s 　 (h) c Hey 1 【H460】 【HCC2429】 (fold) (fold) Radiation dose (Gy) Radiation dose (Gy) (n=3)

Download ppt "Supplementary Figure S1 a"

Similar presentations

Figure 1 HuR Tis11b HPRT VEGF 0 1 2 3 4 5Time (h) A 462 bp (VEGF 165 ) 332 bp (VEGF 121 ) 354 bp 111 bp 305 bp.

Figure 1 HuR Tis11b HPRT VEGF Time (h) A 462 bp (VEGF 165 ) 332 bp (VEGF 121 ) 354 bp 111 bp 305 bp.
Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE1965.810.7 WI380.131.9 MCF10A16.751.9 HCT116115.3177.6 HCT116.

Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE WI MCF10A HCT HCT116.
P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Effects of declining sorafenib levels and dose on acquired reversible resistance and toxicity in hepatocellular carcinoma Elizabeth A. Kuczynski, Christina.

Effects of declining sorafenib levels and dose on acquired reversible resistance and toxicity in hepatocellular carcinoma Elizabeth A. Kuczynski, Christina.
Xenograft TDDoxorubicinCisplatinIfosfamide SGDT/C%EfficacySGDT/C%EfficacySGDT/C%Efficacy OHS40.4620.649>37.60++++ CTPX72.910+++1.625++>4.31++++ SBX6,51.728++0.075>22.14++++

Xenograft TDDoxorubicinCisplatinIfosfamide SGDT/C%EfficacySGDT/C%EfficacySGDT/C%Efficacy OHS > CTPX > SBX6, >
954.502 (z=7) 956.785 (z=7) 956.787 (z=7) 959.073 (z=7) MSMS/MS Ba 7702 Bc AH819 Bc 10987 Bc AH259 b 26 3+ y 33 3+ y 55 5+ b 31 4+ b 9 2+ b 26 3+ y 33.

(z=7) (z=7) (z=7) (z=7) MSMS/MS Ba 7702 Bc AH819 Bc Bc AH259 b y y b b 9 2+ b y 33.
- KLF6 869 bp IHH HepG2 Hep3B HuH-7 900 bp- 800 bp- 700 bp- 600 bp- SV1 715 bp SV2 743 bp SV3 745 bp IHH HepG2 Hep3B HuH-7 0 5 10 15 20 25 Percentage of.

- KLF6 869 bp IHH HepG2 Hep3B HuH bp- 800 bp- 700 bp- 600 bp- SV1 715 bp SV2 743 bp SV3 745 bp IHH HepG2 Hep3B HuH Percentage of.
D Day 2Day 1Day 4Day 6 Day 1 Day 2 Day 4 Day 6 Biopsy Injury D0 D1 D2 D3 D4 D5 D6 Wound monitoring by endoscope & Intrarectal adminstration of LGG or HBSS.

D Day 2Day 1Day 4Day 6 Day 1 Day 2 Day 4 Day 6 Biopsy Injury D0 D1 D2 D3 D4 D5 D6 Wound monitoring by endoscope & Intrarectal adminstration of LGG or HBSS.
Control VEGF 165 b bevacizumab PC3 cells Saline VEGF 165 b A. B. C.D. 0 5 10 15 20 25 30 SalineVEGF 165 b Bevacizumab Vessels/mm -2 ** * Supplementary.

Control VEGF 165 b bevacizumab PC3 cells Saline VEGF 165 b A. B. C.D SalineVEGF 165 b Bevacizumab Vessels/mm -2 ** * Supplementary.
Condition MiaPaCa-2 Control Gem (100nm) AZD1775 (200nM) Gem + AZD1775 Panc-1 Control Gem (50nm) AZD1775 (200nM) Gem + AZD1775 Capan-1 Control Gem (50nm)

Condition MiaPaCa-2 Control Gem (100nm) AZD1775 (200nM) Gem + AZD1775 Panc-1 Control Gem (50nm) AZD1775 (200nM) Gem + AZD1775 Capan-1 Control Gem (50nm)
0 10 20 30 40 50 60 70 80 90 100 013 5 SA-β-Gal positivity (%) Days after 6 Gy of IR exposure 3 Morphology SA-  -Gal 015 Supplementary Fig. S1 A B.

SA-β-Gal positivity (%) Days after 6 Gy of IR exposure 3 Morphology SA-  -Gal 015 Supplementary Fig. S1 A B.
Shimura Supplemental Figure 1

Shimura Supplemental Figure 1
Supplementary Figure 1. (A) Expression of DSB repair proteins

Supplementary Figure 1. (A) Expression of DSB repair proteins
Supplementary data Figure S1 PBMC 20ug PBMC 5ug PBMC 1.25ug PBMC 0.3ug

Supplementary data Figure S1 PBMC 20ug PBMC 5ug PBMC 1.25ug PBMC 0.3ug
Supplementary Figure 1. Importance of first neighbours in breast cancer, hepatocellular carcinoma and non-small cell lung cancer in the SignaLink network.

Supplementary Figure 1. Importance of first neighbours in breast cancer, hepatocellular carcinoma and non-small cell lung cancer in the SignaLink network.
Progesterone receptor

Progesterone receptor
Supplemental Digital Content 4

Supplemental Digital Content 4
Dosimetric and Economic Comparison of Interstitial High-Dose-Rate Brachytherapy to Stereotactic Body Radiation Therapy for Liver Lesions  Brian A. Hrycushko,

Dosimetric and Economic Comparison of Interstitial High-Dose-Rate Brachytherapy to Stereotactic Body Radiation Therapy for Liver Lesions  Brian A. Hrycushko,
Mouse OBK (Serial section)

Mouse OBK (Serial section)

Similar presentations

Ads by Google